

Michael Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2054772/publications.pdf>

Version: 2024-02-01

68
papers

1,232
citations

471509

17
h-index

395702

33
g-index

70
all docs

70
docs citations

70
times ranked

1320
citing authors

#	ARTICLE	IF	CITATIONS
1	Postoperative bleeding complications in patients with hemophilia undergoing major orthopedic surgery: A prospective multicenter observational study. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 857-865.	3.8	14
2	Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results. <i>Blood</i> , 2022, 140, 89-98.	1.4	12
3	Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 Tj ETQq1 1,0.784314 rgBT /Over	2.1	7
4	Left bundle branch pacing preserves ventricular mechanical synchrony better than right ventricular pacing-a two-center study. <i>Europace</i> , 2022, 24, .	1.7	0
5	Thinned-out skin paddle versus collagen matrix as an optimized peri-implant soft tissue following fibula osteoseptocutaneous free flap: 3-year retrospective study. <i>International Journal of Oral and Maxillofacial Surgery</i> , 2021, 50, 391-397.	1.5	1
6	<scp>2021</scp> clinical trials update: Innovations in hemophilia therapy. <i>American Journal of Hematology</i> , 2021, 96, 128-144.	4.1	37
7	Realâ€world data of immune tolerance induction using recombinant factor VIII Fc fusion protein in patients with severe haemophilia A with inhibitors at high risk for immune tolerance induction failure: A followâ€up retrospective analysis. <i>Haemophilia</i> , 2021, 27, 19-25.	2.1	6
8	Prophylaxis for children with moderate hemophilia: Use of a guideline to increase early initiation. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28577.	1.5	0
9	Outcome measures in Haemophilia: Beyond ABR (Annualized Bleeding Rate). <i>Haemophilia</i> , 2021, 27, 87-95.	2.1	23
10	Impact of haemophilia on patients with mildâ€toâ€moderate disease: Results from the Pâ€FIQ and Bâ€HEROâ€S studies. <i>Haemophilia</i> , 2021, 27, 8-16.	2.1	11
11	Improvements in Communication and Coordination of Care in a Hemophilia Treatment Center. <i>Acta Haematologica</i> , 2021, 144, 672-677.	1.4	0
12	Transition of care for pediatric and adult patients with venous thromboembolism: A National Quality Improvement Project from the American Thrombosis and Hemostasis Network (ATHN). <i>Thrombosis Research</i> , 2021, 200, 23-29.	1.7	3
13	Emicizumab initiation and bleeding outcomes in people with hemophilia A with and without inhibitors: A singleâ€center report. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12571.	2.3	8
14	Safety and effectiveness of a risk-stratified venous thromboembolism prophylaxis algorithm in young people with cystic fibrosis. <i>Thrombosis Research</i> , 2021, 206, 36-41.	1.7	3
15	PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant) Tj ETQq1 1 0.784314 rgBT /Over	2.1	5
16	The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors. <i>Haemophilia</i> , 2021, 27, 921-931.	2.1	7
17	Feasibility of Delivering Pediatric-to-Adult Transition Education during Annual Comprehensive Clinic Appointments and Patient-Reported Outcomes: A Quality Improvement Study. <i>Blood</i> , 2021, 138, 2993-2993.	1.4	0
18	Reduced Dosing Frequency Following a Switch to Rix-FP for the Treatment of Hemophilia B: Results from the Athn 2 Study. <i>Blood</i> , 2021, 138, 1039-1039.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Relationship between Endogenous, Transgene FVIII Expression and Bleeding Events Following Valoctocogene Roxaparvovec Gene Transfer for Severe Hemophilia A: A Post-Hoc Analysis of the GENE8-1 Phase 3 Trial. <i>Blood</i> , 2021, 138, 3972-3972.	1.4	0
20	Real-world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years. <i>Haemophilia</i> , 2020, 26, 975-983.	2.1	12
21	Hemophilia without prophylaxis: Assessment of joint range of motion and factor activity. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 1035-1045.	2.3	3
22	Optimal trough levels in haemophilia B: Raising expectations. <i>Haemophilia</i> , 2020, 26, e334-e336.	2.1	6
23	Awareness, Care and Treatment In Obesity maNagement to inform Haemophilia Obesity Patient Empowerment (ACTIONâ€”HOPE): Results of a survey of US haemophilia treatment centre professionals. <i>Haemophilia</i> , 2020, 26, 20-30.	2.1	6
24	Single 2251/4g/Kg Dose Treatment with Eptacog Beta (Factor VIIa, Recombinant) Results in Rapid Hemostasis in Joint Bleeds for Persons with Hemophilia ð or ð with Inhibitors: A PERSEPT1 Subset Analysis. <i>Blood</i> , 2020, 136, 2-3.	1.4	2
25	First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies. <i>Blood</i> , 2020, 136, LBA-6-LBA-6.	1.4	11
26	Inhibit Clinical Trials Platform to Prevent and Eradicate Inhibitors: Feasibility Survey of Current Prophylaxis and Immune Tolerance Practices. <i>Blood</i> , 2020, 136, 14-15.	1.4	0
27	Hemophilia Natural History Study (ATHN 7): Baseline Characteristics, Adverse Events, and Self-Reported Health Status of Individuals with Hemophilia a and B. <i>Blood</i> , 2020, 136, 2-3.	1.4	0
28	Retrospective Chart Review of Gastrointestinal Bleeding in Patients with Von Willebrand Disease. <i>Blood</i> , 2020, 136, 20-21.	1.4	0
29	Meta-analysis of natural, unnatural and cause-specific mortality rates following discharge from inpatient psychiatric facilities. <i>Acta Psychiatrica Scandinavica</i> , 2019, 140, 244-264.	4.5	23
30	Meta-analysis of suicide rates among people discharged from non-psychiatric settings after presentation with suicidal thoughts or behaviours. <i>Acta Psychiatrica Scandinavica</i> , 2019, 139, 472-483.	4.5	21
31	A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. <i>Blood</i> , 2019, 134, 2127-2138.	1.4	241
32	Patient-reported outcomes and joint status across subgroups of <sc>US</sc> adults with hemophilia with varying characteristics: Results from the Pain, Functional Impairment, and Quality of Life (Pâ€”FiQ) study. <i>European Journal of Haematology</i> , 2018, 100, 14-24.	2.2	10
33	Assessments of pain, functional impairment, anxiety, and depression in US adults with hemophilia across patient-reported outcome instruments in the Pain, Functional Impairment, and Quality of Life (Pâ€”FiQ) study. <i>European Journal of Haematology</i> , 2018, 100, 5-13.	2.2	37
34	Impact of pain and functional impairment in <sc>US</sc> adults with haemophilia: Patient-reported outcomes and musculoskeletal evaluation in the pain, functional impairment and quality of life (Pâ€”FiQ) study. <i>Haemophilia</i> , 2018, 24, 261-270.	2.1	36
35	Self-reported prevalence, description and management of pain in adults with haemophilia: methods, demographics and results from the Pain, Functional Impairment, and Quality of life (Pâ€”FiQ) study. <i>Haemophilia</i> , 2017, 23, 556-565.	2.1	90
36	von Willebrand disease Outreach into Integrated Care Education (VOICE): a call to action. <i>Haemophilia</i> , 2017, 23, e370-e373.	2.1	3

#	ARTICLE	IF	CITATIONS
37	Venous thromboembolism in children with cystic fibrosis: Retrospective incidence and intrapopulation risk factors. <i>Thrombosis Research</i> , 2017, 158, 161-166.	1.7	11
38	Safety and dose-dependency of eptacog beta (activated) in a dose escalation study of non-bleeding congenital haemophilia A or B patients, with or without inhibitors. <i>Haemophilia</i> , 2017, 23, 844-851.	2.1	15
39	Arginine vasopressin ameliorates spatial learning impairments in chronic cerebral hypoperfusion via V1a receptor and autophagy signaling partially. <i>Translational Psychiatry</i> , 2017, 7, e1174-e1174.	4.8	25
40	PERSEPT 1: a phase 3 trial of activated eptacog beta for on-demand treatment of haemophilia inhibitor-related bleeding. <i>Haemophilia</i> , 2017, 23, 832-843.	2.1	23
41	Measuring pediatric hematology-oncology fellows' skills in humanism and professionalism: A novel assessment instrument. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26316.	1.5	6
42	Prognostic significance of immune cells in the tumor microenvironment and peripheral blood of gallbladder carcinoma patients. <i>Clinical and Translational Oncology</i> , 2017, 19, 477-488.	2.4	18
43	Reliability of patient-reported outcome instruments in US adults with hemophilia: the Pain, Functional Impairment and Quality of life (P-FiQ) study. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 1603-1612.	1.8	15
44	Identification of patients with congenital hemophilia in a large electronic health record database. <i>Journal of Blood Medicine</i> , 2017, Volume 8, 131-139.	1.7	7
45	Identification of people with acquired hemophilia in a large electronic health record database. <i>Journal of Blood Medicine</i> , 2017, Volume 8, 89-97.	1.7	7
46	Internal consistency and item-total correlation of patient-reported outcome instruments and hemophilia joint health score v2.1 in US adult people with hemophilia: results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 1831-1839.	1.8	27
47	Known-group validity of patient-reported outcome instruments and hemophilia joint health score v2.1 in US adults with hemophilia: results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 1745-1753.	1.8	17
48	The Relationship of Joint Range of Motion to Factor Activity in Patients with Hemophilia A and B without Prophylaxis: A Longitudinal Assessment of the CDC-UDC Hemophilia Dataset. <i>Blood</i> , 2017, 130, 756-756.	1.4	1
49	Association between miR-137 polymorphism and risk of schizophrenia: a meta-analysis. <i>Genetics and Molecular Research</i> , 2016, 15, .	0.2	8
50	Linear and Logistic Regression Models of Patient-Reported Outcomes and Patient Characteristics in US Adults with Hemophilia from the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study. <i>Blood</i> , 2016, 128, 252-252.	1.4	2
51	Breakthrough Bleeding in Hemophilia a Patients on Prophylaxis. <i>Blood</i> , 2016, 128, 2581-2581.	1.4	5
52	Association of TLR2 and TLR4 non-missense single nucleotide polymorphisms with type 2 diabetes risk in a southern Chinese population: a case-control study. <i>Genetics and Molecular Research</i> , 2015, 14, 8694-8705.	0.2	9
53	Humanism and professionalism education for pediatric hematology-oncology fellows: A model for pediatric subspecialty training. <i>Pediatric Blood and Cancer</i> , 2015, 62, 335-340.	1.5	14
54	Malawi Polyomavirus Is a Prevalent Human Virus That Interacts with Known Tumor Suppressors. <i>Journal of Virology</i> , 2015, 89, 857-862.	3.4	21

#	ARTICLE	IF	CITATIONS
55	Identification of Persons with Acquired Hemophilia in a Large Electronic Health Record Database. <i>Blood</i> , 2015, 126, 3271-3271.	1.4	2
56	Impact of Pain and Functional Impairment in US Adult People with Hemophilia (PWH): Patient-Reported Outcomes and Musculoskeletal Evaluation in the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study. <i>Blood</i> , 2015, 126, 39-39.	1.4	3
57	Association between IL2/IL21 and SH2B3 polymorphisms and risk of celiac disease: a meta-analysis. <i>Genetics and Molecular Research</i> , 2015, 14, 13221-13235.	0.2	6
58	Multicentric Castleman Disease Presenting with Fever. <i>Journal of Pediatrics</i> , 2014, 165, 1261-1265.	1.8	9
59	Cardiac findings and long-term thromboembolic outcomes following pulmonary embolism in children: a combined retrospective-prospective inception cohort study. <i>Cardiology in the Young</i> , 2013, 23, 344-352.	0.8	32
60	Treatment of refractory hemorrhage with factor XIII in a patient with hemophilia A with inhibitor. <i>Pediatric Blood and Cancer</i> , 2013, 60, E23-5.	1.5	6
61	Risk factors for in-hospital venous thromboembolism in children: a case-control study employing diagnostic validation. <i>Haematologica</i> , 2012, 97, 509-515.	3.5	101
62	Intestinal Tight Junction in Allograft After Small Bowel Transplantation. <i>Transplantation Proceedings</i> , 2007, 39, 289-291.	0.6	13
63	Acute Influence of FK506 on T-Lymphocyte Populations of Peripheral Blood and Spleen in Rats. <i>Transplantation Proceedings</i> , 2007, 39, 292-294.	0.6	4
64	Manganese superoxide dismutase induction during measles virus infection. <i>Journal of Medical Virology</i> , 2003, 70, 470-474.	5.0	12
65	An amino acid change near the carboxyl terminus of the <i>Streptococcus gordonii</i> regulatory protein Rgg affects its abilities to bind DNA and influence expression of the glucosyltransferase gene <i>gtfG</i> . <i>Microbiology (United Kingdom)</i> , 2003, 149, 399-406.	1.8	17
66	Low-Dose Tissue Plasminogen Activator Thrombolysis in Children. <i>Journal of Pediatric Hematology/Oncology</i> , 2003, 25, 379-386.	0.6	143
67	THE PSYCHOLOGICAL CONSEQUENCES OF AWARENESS DURING SURGERY. , 2000, , .		3
68	The Hemophilia Gene Therapy Patient Journey: Questions and Answers for Shared Decision-Making. <i>Patient Preference and Adherence</i> , 0, Volume 16, 1439-1447.	1.8	12